Mexico declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The archive — 2024
Page 38 of 68 of this archive, newest first.
Zhuhai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Sarcopenia is a diagnosis, not a synonym for losing lean mass
The rule that a quarter of weight lost is lean tissue has been in textbooks for decades and does not survive close reading.
The four testing services and the study none of them can run
Storage instructions in this market are close to uniform and almost never accompanied by the study that would justify them. Uniformity is a sign of convention, not of…
Rapid weight loss moves eight analytes for reasons that have nothing to do with the drug
Which movements are expected, which resolve, and which warrant investigation.
Inspectors cite the consolidator trading as Meridian Freight Partners over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 12-day notice: how a compounding wind-down works in the United Arab Emirates
The document is four pages. Three of them are about dates.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a CPC orforglipron lot at 95.2%, against 92.3% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
Stepping down against stopping: two decisions treated as one
These agents produce no dependence and no withdrawal syndrome. What a taper would be for is therefore a real question rather than an obvious one.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to India after 3 consecutive customs detentions
The route did not close because of a rule about peptides.
What changed at SWB in June, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Janoshik result on a Nantong exenatide lot lands 3.1 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Pancreatitis, obstruction, gallbladder: three things nausea can be
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
What VendorInvestigate charges to answer the pyrogen question
Bacterial endotoxin is a heat-stable lipopolysaccharide from the outer membrane of Gram-negative organisms. It survives sterilisation, passes a sterilising filter, and is…
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
SELECT extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Wuhan export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a SGN liraglutide lot at 95.7%, against 93.4% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
The question no chromatogram has ever answered
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
What “LC-MS: conforms” tells a reader, which is almost nothing
What the Journal asks for when it writes to a supplier about an identity claim, and how often it gets it.
The qualification chain nobody in this trade can show you
Accreditation to the international competence standard covers the scope a laboratory has been assessed for, which is not necessarily the test you commissioned.
STEP 3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 7 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
What the placebo arms of the withdrawal trials actually tell us
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
What a 40% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Wuhan: 12 posters, one theme
Reported from the sessions, and from the two hours afterwards.